The Association Between Arthralgia and Vedolizumab Using Natural Language Processing.

Journal: Inflammatory bowel diseases
PMID: 29846617

Abstract

BACKGROUND: The gut-selective nature of vedolizumab has raised questions regarding increased joint pain or arthralgia with its use in inflammatory bowel disease (IBD) patients. As arthralgias are seldom coded and thus difficult to study, few studies have examined the comparative risk of arthralgia between vedolizumab and tumor necrosis factor inhibitor (TNFi). Our objectives were to evaluate the application of natural language processing (NLP) to identify arthralgia in the clinical notes and to compare the risk of arthralgia between vedolizumab and TNFi in IBD.

Authors

  • Tianrun Cai
    Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA, United States.
  • Tzu-Chieh Lin
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Massachusetts.
  • Allison Bond
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Jie Huang
    Department of Critical Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • Gwendolyn Kane-Wanger
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Massachusetts.
  • Andrew Cagan
  • Shawn N Murphy
  • Ashwin N Ananthakrishnan
    Department of Gastroenterology, Massachusetts General Hospital, MGH Crohn's and Colitis Center, Boston.
  • Katherine P Liao
    Department of Biomedical Informatics, Harvard Medical School, Boston, MA, United States.

Keywords

External Resources

Popular Topics
Recent Journals